Monoamine oxidase inhibitors MAOls

Obsessive compulsive disorder in an 8-year-old can be treated using fluvoxamine (selective serotonin reuptake inhibitor, SSRI). It is usually administered initially os 25 mg daily, and increased if necessary in steps of 25 mg every 4-7 days to a maximum of 200 mg daily. If there is no improvement within 10 weeks, treatment should be reconsidered. A selective serotonin reuptake inhibitor should not be started until 2 weeks after stopping a monoamine oxidase inhibitor (MAOl), and conversely a MAOl should not be started until at least a week after an SSRI has been stopped. 

Monoamine oxidase inhibitor (MAOl) therapy hypersensitivity. 

Switching to or from a monoamine oxidase inhibitor (MAOl) - At least 14 days should elapse between discontinuation of an MAOl and initiation of therapy with mirtazapine. In addition, allow at least 14 days after stopping mirtazapine before starting an MAOl. 

Hypersensitivity to SSRIs in combination with a monoamine oxidase inhibitor (MAOl), or within 14 days of discontinuing an MAOl administration of thioridazine with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued coadministration of fluvoxamine with cisapride, thioridazine or pimozide concomitant use of thioridazine with paroxetine concomitant use of pimozide with sertraline coadministration of sertraline oral concentrate and disulfiram. 

Patients known to be hypersensitive to atomoxetine or other constituents of the product with a monoamine oxidase inhibitor (MAOl) or within 2 weeks after discontinuing an MAOl narrow angle glaucoma (see Warnings). 

Hypersensitivity to brimonidine tartrate or any component of this medication patients receiving monoamine oxidase inhibitor (MAOl) therapy. 

Contraindications Coadministration with monoamine oxidase inhibitors (MAOls), hypersensitivity to dextromethorphan or its components... 

SRls are currently the most prevalent pharmacological treatment used for panic disorder [see Westenberg and Den Boer, Chapter 24, in this volume], even though tricyclic antidepressants, monoamine oxidase inhibitors [MAOls], and benzodiazepines are also effective. The efficacy of the SRI antidepressants and the observation that initially they may induce deterioration of symptoms [which is usually not the case with treatment of depressed patients with the same medications] raise issues related to the pathobiology of anxiety and its comorbidity with depression. 

Monoamine oxidase inhibitors [MAOls] have been historically the most extensively studied class of medications directed against social anxiety. Early... 

Monoamine oxidase inhibitor (MAOl) A drug that inhibits the enzyme monoamine oxidase (MAO), thereby increasing the level of neurotransmitters and drugs metabolized by MAO. 

Although behavioral treatments for social phobia have been well studied, there are very limited data on its pharmacological management, b- Blockers (propranolol, atenolol) have been recommended, but available evidence indicates their effect may be no different than that of placebo ( 78). In a controlled study, the monoamine oxidase inhibitor (MAOl) phenelzine has been shown to be more effective than placebo (78, 79). Anecdotal reports have also described efficacy with alprazolam, clonidine, and fluoxetine, but systematic data are lacking (80, 81, 82 and 83). 

The first class of antidepressants was developed in the early 1950s with the discovery of an antitubercular drug iproniazid that possesses mood-elevating properties (Nutt, 2002). Iproniazid is a monoamine oxidase inhibitor (MAOl). Monoamine oxidase is the enzyme that breaks down serotonin, dopamine, and norepinephrine. The inhibition of monoamine oxidase increases levels of monoamines in the synapse. 

Monoamine oxidase inhibitors (MAOl) o Nialamide (Niamide) N -(2-BenzylcarbamoyT ethyl)isonicotinohydrazide o Tranylcypromine (Parnate) (+ )-fra s-2-Phe-nylcyclopropylamine sulfate (2 1) o Iproniazid (Marsilid) 2 -lsopropylisonicotino-hydrazide... 

PSYCHOTROPIC, and also a veterinary immobilizing agent. It is a drug of abuse, largely withdrawn from human clinical use. phencyclidine hydrochloride phencyclidine, phenelzine [ban, inn] (phenelzine sulfate [usan] Nardil ) is one of the hydrazine class and is an irreversible MONOAMINE-OXIDASE INHIBITOR (MAOl active against both A and 6) used as an ANTIDEPRESSANT. 

Degradation (e.g. monoamine oxidase inhibitors, MAOls, preverrt the breakdown of monoamine nettrotransmitters). 

Selective serotonin reuptake inhibitors (SSRIs) are the first-line therapy for PTSD. Efficacy for fluoxetine, paroxetine, and sertraline has been demonstrated in well-designed double-blind placebo-controlled studies to reduce all symptom domains (intrusive recollection, avoidance/numbness, and hyperarousal). - Other treatment options include the tricyclic antidepressants (TCAs) amitriptyline and imipramine and the irreversible monoamine oxidase inhibitor (MAOl) phenelzine, which have been shown to reduce re-experiencing. However, in comparison with SSRIs, TCAs and phenelzine are associated with a higher incidence of side-effects, risk of overdose, and poor compliance. Alprazolam has demonstrated anecdotal efficacy however, regular use of benzodiazepines is not recommended. Benzodiazepines can be used on an as-needed basis for specific symptoms (e.g. sleep disturbances). CBT has shown beneficial effects in relatively well-controlled studies, while the results with exposure therapy are... 

Concomitant use of monoamine oxidase inhibitors (MAOls) or within 14 days after their discontinuation is contraindicated as hyperpyretic crisis, seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) and MAOls. 

---